Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BNT211 |
| Synonyms | |
| Therapy Description |
BNT211 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CLDN6 and a CAR T-cell amplifying RNA vaccine expressing CLDN6, which potentially inhibits tumor growth and enhances antitumor immune response (PMID: 31896660, Journal for ImmunoTherapy of Cancer 2021;9). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BNT211 | BNT 211|BNT-211 | BNT211 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CLDN6 and a CAR T-cell amplifying RNA vaccine expressing CLDN6, which potentially inhibits tumor growth and enhances antitumor immune response (PMID: 31896660, Journal for ImmunoTherapy of Cancer 2021;9). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04503278 | Phase I | BNT211 CLDN6 CAR T-cells | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | Recruiting | SWE | NLD | DEU | AUS | 0 |